Learn languages naturally with fresh, real content!

tap to translate recording

Explore By Region

flag Hemogenyx expands its CAR-T trial to children with relapsed leukemia, based on adult safety data.

flag Hemogenyx Pharmaceuticals has received approval to expand its Phase I trial of HG-CT-1, a CAR-T therapy for relapsed or refractory acute myeloid leukemia, to include pediatric patients. flag The amendment, cleared by MD Anderson’s Institutional Review Board, allows enrollment of children and adolescents based on safety and early efficacy data from adult trials. flag The move marks a key step in advancing treatment options for younger patients, for whom therapies remain limited. flag The company, based in London with U.S. operations in New York City, plans to provide updates as enrollment progresses in both adult and pediatric groups.

13 Articles